Bayer will focus on paying down debt and not make any major acquisitions in the next two or three years, the head of the ...

These launches are what Oelrich called “must-win battles” at Bayer as the Xarelto loss of exclusivity reaches “full swing” in ...

Bayer expects its pharmaceutical business to return to growth in 2027 as the launch new therapies is expected to offset ...

The pharmaceutical company’s latest partnership with Incremental and Skai drove a 32% boost in iROI, delivering nearly a third more sales per ad dollar.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

Despite restructuring efforts, Bayer's financial outlook for 2025 remains ... Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.

It will also take ownership of a contract business in the US, where Endo Pharmaceuticals licenses Nebido from Bayer and sells it under the Aveed brand name. The two companies said the transaction ...

Bayer's Global Capability Centre in Hyderabad contributes to R&D, data science, and AI-driven healthcare solutions, ...

Bayer’s deal with Genpact opens up new ground for pharma’s use of artificial intelligence ... as with last month’s collaboration between Orbita and a US hospital. The FDA has placed the ...